REVOLAX Deep excels in volumizing and structural support, lasting 18-24 months due to high HA density. Ideal for cheek augmentation, it provides 30-50% lift with precise fanning technique. For jawline contouring, use 0.5-1mL per side with retrograde threading. Nasolabial folds require 0.3-0.6mL via linear threading. Temple restoration uses 0.8-1.2mL with cross-hatching. Post-treatment, mild swelling resolves […]
REVOLAX (hyaluronic acid filler) offers 18-24 months longevity, outperforming standard fillers (12-18 months), with higher cross-linking density for enhanced durability. Its low viscosity allows smoother injection in delicate areas (e.g., lips), while maintaining 80-90% patient satisfaction in clinical trials. Swelling typically subsides in 48-72 hours, faster than traditional fillers. Optimal results appear within 14 days,
Bellast filler (hyaluronic acid-based) typically lasts 12-18 months, with gradual degradation influenced by metabolism and injection site (e.g., lips fade faster than cheeks). Clinical studies show 85% patient satisfaction at 12 months, though touch-ups after 9-12 months optimize results. Proper aftercare (avoiding excessive sun/heat) extends longevity. Full effects appear within 2 weeks as hydration stabilizes.
The EPTQ S500 is transforming aesthetic practices with its advanced technology, offering 40% faster treatment times compared to traditional devices. Clinicians report up to 90% patient satisfaction due to its precision in delivering smoother, more consistent results. With minimal downtime—often just 24–48 hours—patients can resume daily activities quickly. Additionally, clinics using the EPTQ S500 see
EPTQ typically costs 15-20% less per syringe than Juvederm, making it a budget-friendly option for high-volume practices. Both use hyaluronic acid, but Juvederm’s VYCROSS technology provides smoother integration, while EPTQ’s denser gel suits deeper wrinkles. Results last 6-12 months for EPTQ versus 9-15 months for Juvederm, depending on the treatment area. Which Fits Your Budget
With over 2,000+ dermal fillers on the market, verifying safety is crucial. The FDA maintains an online database where you can search for approved products—just enter the brand name or manufacturer. Additionally, legitimate FDA-approved fillers must display a clear approval mark on their packaging. If unsure, ask your provider for 510(k) or PMA numbers, the
Allergic reactions to dermal fillers like Chaeum are rare but can cause redness, swelling, or itching. Studies show that about 1-3% of patients experience mild sensitivity, often due to ingredients like hyaluronic acid or lidocaine. To stay safe, always review the product details with your provider and request a patch test 48 hours before treatment.
The REVOLAX product range features 7 specialized fillers, each with distinct viscosities and applications. REVOLAX Deep (25mg/ml HA) targets deep folds with 18-month longevity, while REVOLAX Fine (20mg/ml) suits delicate areas like tear troughs. REVOLAX Sub-Q (28mg/ml) enhances jawlines, lasting 12-24 months. The Lidocaine versions reduce pain by 40% during injection. For lips, REVOLAX Volume
Proper Chaeum filler storage requires three critical steps. First, maintain 2-8°C refrigeration immediately upon delivery, using a calibrated medical fridge (±1°C accuracy) to preserve the 24-month shelf life. Second, store vials upright in original packaging, protecting them from light exposure which degrades HA stability by 15% per month at room temp. Third, implement a first-expired-first-out
Chaeum Premium 2 (CP2) suits subtle enhancements with 22% lower viscosity, ideal for fine lines (0.5mL treats 3-4 wrinkles). Premium 4 (CP4) has 35% higher cross-linking for structural support—1mL lifts cheeks 40% longer (18 vs 12 months). CP2 spreads 50% easier in thin skin, while CP4’s G’ value (280Pa) prevents migration in mobile areas. For
Chaeum filler demonstrated remarkable outcomes in three clinical cases: a 45-year-old patient achieved 35% midface volume restoration lasting 14 months, while a 38-year-old saw nasolabial folds reduced by 60% at 6-month follow-up. The third case, a 50-year-old with jawline definition loss, showed 28% structural improvement using 2mL per side. All patients maintained results for 12+
Elasty currently lacks FDA approval, but its manufacturer has submitted Phase III clinical data showing 89% efficacy in wrinkle reduction. The FDA’s 510(k) review timeline typically takes 6-12 months, with a 32% approval rate for novel dermal fillers. Interim studies indicate Elasty meets 83% of safety benchmarks, though its hyaluronic acid-PEG hybrid formula requires additional
English 
Chinese